(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.77%.
60 Degrees Pharmaceuticals's earnings in 2026 is -$8,616,152.On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$11,335,956, with the lowest SXTP earnings forecast at -$10,960,341, and the highest SXTP earnings forecast at -$11,595,509. On average, 3 Wall Street analysts forecast SXTP's earnings for 2027 to be -$1,937,157, with the lowest SXTP earnings forecast at -$1,861,190, and the highest SXTP earnings forecast at -$1,994,132.
In 2028, SXTP is forecast to generate -$1,578,424 in earnings, with the lowest earnings forecast at -$1,516,525 and the highest earnings forecast at -$1,624,848.